Upadacitinib Is Associated with the Lowest Risk of Treatment Failure Among Advanced Therapies for Ulcerative Colitis: A Real-World Administrative Claims Study.
BACKGROUND AND AIMS We compared the real-world effectiveness of advanced therapies (AT) in patients with ulcerative colitis (UC). METHODS Using the OptumLabs® Data Warehouse, a nationally representative US administrative claims database, we identified patients with UC initiating infliximab, adalimumab, vedolizumab, u...